Full Text
Abstract
Introduction. Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease that characterized by an aggressive course. Lesion of liver tissue affects on coagulation becouse this organ plays a central role in hemostasis.
Aim: to study hemostatic disturbances in the development of fibrosis and cirrhosis in children with AIH.
Materials and methods. The study included 29 patients (3–17 years old): 16 (55%) girls and 13 (45%) boys. The first group consisted of 13 children with F 0–2 degree of fibrosis (according to Metavir scale); the second group consisted of 16 patients with F 3–4 degree of fibrosis (according to Metavir scale), in this group of children liver cirrhosis was diagnosed. The control group consisted of 15 children related to I or II groups of health. The state of endothelium, hemocoagulation, endogenous an- ticoagulants and fibrinolysis were assessed in all children.
Results. In children with AIH and early stages of liver fibrosis hemostasis disorders were characterized by increased activity of von Willebrand factor (VWF), increased levels of antithrombin III and fibrinogen, prolongation of prothrombin Quick test (PT) and activated partial thromboplastin time (APTT). The development of liver cirrhosis in AIG was accompanied by increased activity of VWF, decreased activity of protein C, prolongation of PT and APTT.
Conclusion. In children with AIG disorders are detected affecting the endothelial, coagulation and anticoagulant hemostasis that correlated with the severity of pathological process.
REFERENCES
1. Muratori P., Lenzi M., Cassani F. et al. Diagnostic approach to auto- immune hepatitis. Expert Rev Clin Immunol. 2017; 13 (8): 769–79. 2. Deswal S., Srivastava A. Role of Allopurinol in Optimizing Thio- purine Therapy in Patients with Autoimmune Hepatitis: A Review.
J Clin Exp Hepatol. 2017; 7 (1): 55–62.
3. Thuluvath P. J., Wagennar R. R., Verma S. Gender and ethnic differ-
ences in the post-liver transplant outcomes of patients with auto- immune hepatitis with acute liver failure at initial presentation: a case-control study. Arch Med Sci. 2015; 11 (6): 1227–35.
4. Klyaritskaya I. L., Shelikhova E. O., Semenikhina E. V. Diagnosis of autoimmune hepatitis according to the recommendations of EASL 2015. [Diagnostika autoimmunnogo gepatita soglasno rekomen- daciyam EASL 2015]. Krymskij terapevticheskij zhurnal. 2014; 4: 9–17 (in Russ.).
5. Christen U., Hintermann E. Immunopathogenic Mechanisms of Autoimmune Hepatitis: How Much Do We Know from Animal Models? Int J Mol Sci. 2016; 17 (12): 1–19.
6. Shirokova E. N., Ivashkin K. V., Ivashkin V. T. Autoimmune hep- atitis: new in diagnosis, pathogenesis and treatment. [Autoim- munnyj gepatit: novoe v diagnostike, patogeneze i lechenii]. Ros- sijskij zhurnal gastroenterologii, gepatologii, koloproktologii. 2012; 5: 37–45 (in Russ.).
7. Ivashkin V. T., Maevskaya M. V., Pavlov Ch. S. et al. Clinical rec- ommendations of the Russian Society for Liver Study and the Rus- sian Gastroenterological Association for the Treatment of Liver
Cirrhosis Complications. [Klinicheskie rekomendacii Rossijsk- ogo obshchestva po izucheniyu pecheni i Rossijskoj gastroenter- ologicheskoj associacii po lecheniyu oslozhnenij cirroza pecheni]. Gepatologiya. 2016; 26 (4): 71–100 (in Russ.).
8. Musin A. G., Mutalova E. G., Nigmatullina A. E. et al. Modern aspects of mechanisms of fibrogenesis in the liver. [Sovremennye aspekty mekhanizmov fibrogeneza v pecheni]. Medicinskij vestnik Bashkortostana. 2014; 9 (3): 95–9 (in Russ.).
9. Mekhtiev S. N., Stepanenko V. V., Zinovieva E. N., Mekhtie- va O. A. Modern ideas about liver fibrosis and methods of its cor- rection. [Sovremennye predstavleniya o fibroze pecheni i metodah ego korrekcii]. Farmateka. 2014; 6: 80–7 (in Russ.).
10. Leonardi F., Maria N., Villa E. Anticoagulation in cirrhosis: a new paradigm? Clin Mol Hepatol. 2017; 23 (1): 13–21.
11. Kurkina I. A., Maevskaya M. V., Ivashkin V. T. Hypercoagulation and thrombosis in patients with cirrhosis of the liver. [Giper- koagulyaciya i tromboz u bol’nyh cirrozom pecheni]. Poliklini- ka (specvypusk «Gastroehnterologiya»). 2015; 3: 21–5 (in Russ.).
12. Bouomrani S., Farah A., Bouassida N. et al. Portal vein thrombo- sis in a type 1 autoimmune hepatitis. Pan Afr Med J. 2013; 14: 130. 13. Enger C., Forssen U. M., Bennett D. et al. Thromboembolic events among patients with hepatitis C virus infection and cirrhosis: a matched-cohort study. Adv Therapy. 2014; 31 (8): 891–903.
14. Chegai F., Cavallo A. U., Forcina M. et al. Giant Splenorenal Shunt in a Young Patient with Autoimmune Hepatitis/Primary Biliary Cholangitis Overlap Syndrome and Portal Vein Thrombosis. Case Rep Radiol. 2017; 2017: 2167364.
15. Wang C. C., Chang C. T., Lin C. L. et al. Hepatitis C Virus Infection Associated With an Increased Risk of Deep Vein Thrombosis. Medicine (Baltimore). 2015; 94 (38): e1585.
16. Tana M. M., Zhao X., Bradshaw A. et al. Factors associated with the platelet count in patients with chronic hepatitis C. Thromb Res. 2015; 135 (5): 823–8.
17. Batyrova A. S., Bakanov M. I., Surkov A. N. Modern ideas about the system of hemostasis in chronic liver diseases. [Sovremennye predstavleniya o sisteme gemostaza pri hronicheskih zabolevani- yah pecheni]. Klinicheskaya laboratornaya diagnostika. 2015; 60 (8): 40–4 (in Russ.).
18. González-Reimers E., Quintero-Platt G., Martín-González C. et al. Thrombin activation and liver inflammation in advanced hepatitis C virus infection. World J Gastroenterol. 2016; 22 (18): 4427–37.
19. Mancuso A. The ischemic liver cirrhosis theory and its clinical implications. Med Hypotheses. 2016; 94: 4–6.
20. Bilalova R. A. Features of the clinic and hemostasis system in patients with chronic hepatitis and cirrhosis. [Osobennosti klini- ki i sistemy gemostaza u bol’nyh hronicheskimi gepatitami i cir- rozom pecheni]. Avtoref. dis. kand. med. nauk. Moskva. 2015: 23 s (in Russ.).
21. Palta S., Saroa R., Palta A. Overview of the coagulation system. Indian J Anaesth. 2014; 58 (5): 515–23.
22. Koroy P. V. Clinico-pathogenetic and prognostic significance of hemostatic homeostasis disorders in chronic liver diseases. [Kliniko- patogeneticheskoe i prognosticheskoe znachenie narushenij gemo- staticheskogo gomeostaza pri hronicheskih zabolevaniyah peche- ni]. Avtoref. dis. dokt. med. nauk. Stavropol’. 2010: 41 s (in Russ.).
23. Ivannikov V. V. Some pathogenetic mechanisms of plasma hemo- stasis disorders and their diagnosis in chronic hepatitis and liver cirrhosis. [Nekotorye patogeneticheskie mekhanizmy narushenij plazmennogo gemostaza i ih diagnostika pri hronicheskih gepa- titah i cirrozah pecheni]. Avtoref. dis. kand. med. nauk. Astrah- an’. 2014: 23 s (in Russ.).
24. Nielsen N. S., Jespersen S., Gaardbo J. C. et al. Impaired Platelet Aggregation and Rebalanced Hemostasis in Patients with Chron- ic Hepatitis C Virus Infection. Int J Mol Sci. 2017; 18 (5): 1016.
25. Levy J. H., Sniecinski R. M., Welsby I. J., Levi M. Antithrombin: anti-inflammatory properties and clinical applications. Thromb Haemost. 2016; 115 (4): 712–28.
26. Massoud O. I., Zein N. N. The Effect of Transjugular Intrahepat- ic Portosystemic Shunt on Platelet Counts in Patients With Liver Cirrhosis. Gastroenterol Hepatol. 2017; 13 (5): 286–91.
27. Zubairov D. M., Zubairova L. D. Microvesicles in the blood. Func- tions and their role in thrombogenesis: monograph. [Mikrovezi- kuly v krovi. Funkcii i ih rol’ v tromboobrazovanii: monografiya]. Moskva: GEOTAR-Media. 2009: 167 s (in Russ.).
28. Wu H., Yan S., Wang G. et al. Von Willebrand factor as a novel noninvasive predictor of portal hypertension and esophageal var- ices in hepatitis B patients with cirrhosis. Scand J Gastroenter- ol. 2015; 50 (9): 1160–9.